Zenas BioPharma Short Interest Surges 21% in March

Biotech firm faces increased short selling activity amid market volatility

Apr. 17, 2026 at 8:34am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of metal gears, levers, and machinery, conveying the intricate and high-stakes nature of biotech investments without using any text or identifiable elements.The rise in short interest for Zenas BioPharma reflects the volatility and uncertainty surrounding the biotech sector, as investors scrutinize the industry's financial infrastructure.Cambridge Today

Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage biotechnology company, saw a significant increase in short interest during March, with the number of shares shorted rising 21.4% to 9,362,107 as of March 31st. This represents 20.9% of the company's total outstanding shares, with the short-interest ratio currently at 7.5 days based on average daily trading volume.

Why it matters

The rise in short interest for Zenas BioPharma reflects broader market volatility and uncertainty surrounding the biotech sector. Short sellers may be betting against the company's future prospects or looking to capitalize on potential stock price declines. This activity can impact the stock's performance and make it more difficult for the company to raise capital.

The details

Zenas BioPharma, a Massachusetts-based biotech firm, has seen its short interest increase significantly over the past month. As of March 31st, there were 9,362,107 shares shorted, up 21.4% from the 7,709,823 shares shorted as of March 15th. This represents about 20.9% of the company's total outstanding shares, with the short-interest ratio currently at 7.5 days based on the stock's average daily trading volume of 1,251,928 shares.

  • As of March 31st, 2026, Zenas BioPharma had 9,362,107 shares shorted.
  • On March 15th, 2026, Zenas BioPharma had 7,709,823 shares shorted.

The players

Zenas BioPharma, Inc.

A clinical-stage biotechnology company focused on developing novel therapies in oncology and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

The surge in short interest for Zenas BioPharma reflects the volatility and uncertainty surrounding the biotech sector, as investors may be betting against the company's future prospects or looking to capitalize on potential stock price declines. This activity can impact the stock's performance and make it more difficult for the company to raise capital, underscoring the challenges faced by early-stage biotech firms.